Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Amgen鈥檚 latest 10-K can feel like navigating a clinical-trial protocol鈥攈undreds of pages on biologics manufacturing, FDA milestones and patent cliffs. If you鈥檝e ever searched for 鈥淎mgen insider trading Form 4 transactions鈥� or tried to pinpoint R&D spend buried deep in a footnote, you know the challenge. Biotech disclosures are dense because every molecule, royalty agreement and safety signal can move AMGN鈥檚 valuation.
Stock Titan turns those complexities into clarity. Our AI-powered summaries spotlight what matters in each Amgen SEC filing鈥攚hether it鈥檚 a 鈥渜uarterly earnings report 10-Q filing鈥� that explains Prolia sales trends or an 鈥�8-K material events explained鈥� alert when a Phase 3 study stops early. AG真人官方-time feeds surface 鈥淎mgen Form 4 insider transactions real-time鈥� so you can monitor executive stock transactions before the market reacts. Need the big picture? The 鈥渁nnual report 10-K simplified鈥� section distills pipeline probabilities, biosimilar headwinds and manufacturing capacity in plain English.
Use the platform to:
- Scan 鈥淎mgen proxy statement executive compensation鈥� details to see how scientists are incentivized.
- Compare segment margins across quarters with our 鈥淎mgen earnings report filing analysis鈥�.
- Dive into 鈥淎mgen SEC filings explained simply鈥� for each form type鈥攆rom S-8 share plans to 10b5-1 trading plans.
No more rummaging through PDFs. With real-time updates from EDGAR and AI that translates biotech jargon, understanding Amgen SEC documents with AI becomes straightforward鈥攈elping investors, analysts and healthcare professionals make informed decisions faster.
Nancy A. Grygiel, SVP & CCO of Amgen Inc. (AMGN), reported a sale of common stock on 08/20/2025. The filing shows 1,267 shares were disposed of at a price of $296.985 per share. After this transaction the reporting person directly beneficially owned 7,209 shares.
The filing also discloses an indirect interest of 103.8077 shares held through Amgen's 401(k) plan. The report notes that 80 dividend equivalents were credited to unvested RSUs and are paid in shares per the company plan.
Amgen Inc. (AMGN) Form 144 notice reports a proposed sale of 1,267 shares of common stock through Raymond James & Associates on 08/20/2025 with an aggregate market value of $372,908.81. The shares were acquired from the issuer on 03/18/2024 via RSE/DEU grants and paid in cash. The filing lists 538,360,000 shares outstanding. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Amgen director S. Omar Ishrak reported the acquisition of 121.4308 shares of Amgen common stock on 08/08/2025 via vested restricted stock units under the Amgen Inc. 2009 Director Incentive Program. The transaction is shown at a $0 price, reflecting issuance of shares upon vesting, and the Form 4 was signed on 08/09/2025.
The filing reports 6,241.9302 shares beneficially owned following the transaction, held directly. The reported shares include 291 Dividend Equivalents credited to vested but deferred RSUs and payable in shares under a dividend reinvestment arrangement. The document identifies the reporting person as a director of Amgen (AMGN).
On 08/08/2025 Amgen director Charles M. Holley reported the immediate vesting of restricted stock units (RSUs) granted under Amgen's Director Incentive Program. The vested RSUs were converted to common stock on a one-for-one basis and recorded as an acquisition (transaction code A) with a reported price of $0.
Following the reported transaction Holley beneficially owns 11,469.6259 shares directly and 1,260 shares indirectly through the Holley Family Trust. The filing also shows 1,294 Dividend Equivalents credited to vested but deferred RSUs, which are payable in shares one-for-one with cash for any fractional share amounts.
Michael V. Drake, a director of Amgen Inc. (AMGN), reported the vesting and conversion of Restricted Stock Units into 121.4308 shares on 08/08/2025. The vested RSUs convert one-for-one into common stock and were reported at a purchase price of $0, reflecting compensation rather than an open-market trade. After the transaction his direct beneficial ownership is reported as 4,699.0291 shares. The reported amount includes 227 Dividend Equivalents credited on vested-but-deferred RSUs that are paid in shares under the Director Incentive Program and the Amgen Inc. 2009 Equity Incentive Plan.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
